SXI Life Sciences
6.379,55
PKT
+14,65
PKT
+0,23
%
Werbung
Analysen zu SXI Life Sciences-Werten
Datum | Rating | Analyst | |
---|---|---|---|
28.04.21 | Novartis Neutral | Credit Suisse Group | |
28.04.21 | Novartis buy | Deutsche Bank AG | |
28.04.21 | Novartis Underweight | JP Morgan Chase & Co. | |
27.04.21 | Novartis buy | Jefferies & Company Inc. | |
27.04.21 | Roche Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
27.04.21 | Novartis Underweight | JP Morgan Chase & Co. | |
27.04.21 | Novartis Underweight | Barclays Capital | |
27.04.21 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
27.04.21 | Novartis buy | UBS AG | |
27.04.21 | Novartis market-perform | Bernstein Research | |
23.04.21 | Roche buy | Goldman Sachs Group Inc. | |
23.04.21 | Roche Halten | DZ BANK | |
23.04.21 | Roche Neutral | JP Morgan Chase & Co. | |
22.04.21 | Roche Neutral | Credit Suisse Group | |
22.04.21 | Novartis Underweight | JP Morgan Chase & Co. | |
22.04.21 | Roche Neutral | Credit Suisse Group | |
21.04.21 | Roche Hold | Jefferies & Company Inc. | |
21.04.21 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
21.04.21 | Roche overweight | Barclays Capital | |
21.04.21 | Roche Neutral | JP Morgan Chase & Co. | |
21.04.21 | Roche Outperform | Bernstein Research | |
19.04.21 | Roche Neutral | JP Morgan Chase & Co. | |
09.04.21 | Novartis Underweight | JP Morgan Chase & Co. | |
07.04.21 | Roche Neutral | JP Morgan Chase & Co. | |
07.04.21 | Novartis Underweight | JP Morgan Chase & Co. | |
24.03.21 | Roche overweight | Barclays Capital | |
24.03.21 | Roche Neutral | JP Morgan Chase & Co. | |
24.03.21 | Roche Conviction Buy | Goldman Sachs Group Inc. | |
23.03.21 | Roche Neutral | JP Morgan Chase & Co. | |
23.03.21 | Novartis Underweight | JP Morgan Chase & Co. | |
23.03.21 | Novartis buy | Jefferies & Company Inc. | |
23.03.21 | Novartis market-perform | Bernstein Research | |
23.03.21 | Roche Outperform | Bernstein Research | |
23.03.21 | Roche Neutral | UBS AG | |
23.03.21 | Roche Hold | Deutsche Bank AG | |
23.03.21 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
23.03.21 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
22.03.21 | Roche overweight | Barclays Capital | |
22.03.21 | Novartis market-perform | Bernstein Research | |
22.03.21 | Roche Neutral | UBS AG |